Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

Psychiatry Research - Neuroimaging

Volumn 75, Issue 2, 1997, Pages 91-101

  Knable, Michael B ^a   Heinz, Andreas ^a   Raedler, Thomas ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antipsychotics; I 123 IBZM; Neuroleptics; Schizophrenia; SPECT

Indexed keywords

BENZATROPINE; CARBAMAZEPINE; CLOZAPINE; DESIPRAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; IMIPRAMINE; LISINOPRIL; LITHIUM; LORAZEPAM; METOPROLOL; PAROXETINE; PERPHENAZINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZAMIDES; BRAIN; BRAIN MAPPING; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RISPERIDONE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030770818     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(97)00023-1     Document Type: Article

References (35)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association Press, Washington, D.C.
2. Andreasen, N.C., 1984. Scale for the Assessment of Negative Symptoms. University of Iowa, Iowa City.
3. Bigelow, L.B., Berthot, B.D., 1989. The psychiatric symptom assessment scale. Psychopharmacology Bulletin 25, 168-179.
4. Borison, R.L., Pthijaram, A.P., Diamond, B.I., Meibach, R.C., 1992. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin 28, 213-218.
5. Brücke, T.R.J., Roth, J., Podreka, I., Strobl, R., Wenger, S., Asenbaum, S., 1992. Striatal dopamine D2 receptor blockade by typical and atypical neuroleptics. Lancet 339, 497.
6. Castelao, J.F., Ferreira, L., Gelders, Y.G., Heylen, S.L.E., 1989. The efficacy of the D2 and 5-HT2 antagonist risperidone (R64766) in the treatment of chronic psychosis: an open dose-finding study. Schizophrenia Research 2, 411-415.
7. Chouinard, G., Jones, B., Remngton, G., et al., 1993. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 13, 25-40.
8. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry 45, 71-76.
9. Farde, L., Nordström, A.-L., Wiesel, F.-A., Pauli, S., Halldin, C., Sedvall, G., 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
10. Frost, J.J., Rosier, A.J., Reich, S.G., et al., 1993. Positron emission tomographic imaging of the dopamine transporter with 11-C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Annals of Neurology 34, 423-431.
11. Gibb, W.R.G., 1992. Neuropathology of Parkinson's disease and related syndromes. In: Cedarbaum, J.M., Gancher, S.T. (Eds.), Parkinson's Disease, Neurologic Clinics, Vol. 10, Saunders, Philadelphia, pp. 361-376.
12. Janssen, P.A.J., Niemeggers, C.J.E., Awouters, F.H.L., Schellekens, K.H.L., Megens, A.A.H.P., Meert, T.F., 1988. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin S2 and dopamine D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 244, 685-693.
13. Jellinger, K., 1986. Overview of morphologic changes in Parkinson's disease. In: Yahr, M.D., Bergman, K.J. (Eds.), Advances in Neurology, Vol. 45, Raven Press, New York, pp. 1-18.
14. 2-dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sciences 57, 103-107.
15. Klemm, E., Grunwald, F., Kasper, S., et al., 1996. I-123 IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. American Journal of Psychiatry 153, 183-190.
16. Knable, M.B., Jones, D.W., Coppola, R., et al., 1995. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. Journal of Nuclear Medicine 36, 1216-1225.
17. Kung, M.P., Kung, H., 1989. Peracetic acid as a superior oxidant for preparation of I-123-IBZM; a potential dopamine D2 receptor imaging agent. Journal of Radiopharmaceutical Lab Comp 27, 691-700.
18. Laruelle, M., van Dyck, C., Abi-Dargham, A., et al., 1994. Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. Journal of Nuclear Medicine 35, 743-754.
19. Leysen, J.E., Gommeren, W., Eens, A., de Chaffoy de Courcelles, D., Stoof, J.C., Janssen, P.A.J., 1988. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 247, 661-670.
20. Marder, S.R., Meibach, R., 1994. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 151, 825-835.
21. Marek, K.L., Seibyl, J.P., Zoghbi, S.S., et al., 1996. 123-I-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46, 231-237.
22. Megens, A.A.H.P., Awouters, F.H.L., Niemeggers, C.J.E., 1988. Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol. Psychopharmacology 95, 493-496.
23. Mesotten, F., Suy, E., Pietquin, M., Burton, P., Heylen, S., Gelders, Y., 1989. Therapeutic effect and safety of increasing doses of risperidone. Psychopharmacology 99, 445-449.
24. Nordström, A.-L., Farde, L., Wiesel, F.-A., et al., 1993. Central D2 dopamine receptor occupancy in relation to antipsychotic drug effects: a double blind PET study of schizophrenic patients. Biological Psychiatry 33, 227-235.
25. Nordström, A.-L., Farde, L., Nyberg, S., Karlsson, P., Halldin, C., Sedvall, G., 1995. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. American Journal of Psychiatry 152, 1444-1449.
26. 2-dopamine receptor occupancy in the living human brain. Psychopharmacology 110, 265-272.
27. 2 dopamine receptor occupancy during low dose treatment with haloperidol decanoate. American Journal of Psychiatry 152, 173-178.
28. Pickar, D., Su, T.-P., Weinberger, D.R., et al., 1996. Individual variation in D2 occupancy in clozapine treated patients. American Journal of Psychiatry 153, 1571-1578.
29. Pilowsky, L.S., Costa, D.C., Ell, P.J., Murray, R.M., Verhoeef, N.L.P.G., Kerwin, R.W., 1992. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340, 199-202.
30. Roose, K., Gelders, Y., Heylen, S., 1988. Risperidone (R64766) in psychotic patients: a first clinical therapeutic exploration. Acta Psychiatrica Belgica 88, 233-241.
31. Scherer, J., Tatsch, K., Schwartz, J., Oertel, W., Kirsch, M.C., Albus, M., 1994. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biological Psychiatry 36, 627-629.
32. van Woert, M.H., 1983. Neuroleptics in neurologic disorders. In: Coyle, J.T., Enna, SJ. (Eds.), Neuroleptics: Neurochemical, Behavioral, and Clinical Perspectives. Raven Press, New York, pp. 65-74.
33. Wolf, S.S., Jones, D.W., Knable, M.B., et al., 1996. Tourette's syndrome: caudate D2 receptor binding explains phenotypic variation in monozygotic twins. Science 273, 1225-1227.
34. Wolkin, A., Brodie, J.D., Barouche, F., Rotrosen, J., Wolf, A.P., Smith, M., Fowler, J., Cooper, T.B., 1989. Dopamine receptor occupancy and plasma haloperidol levels. Archives of General Psychiatry 46, 482-483.
35. Wyatt, R.J., 1993. Practical Psychiatric Practice: Clinical Interview Forms, Rating Scales and Patient Handouts. American Psychiatric Association Press, Washington, D.C.